The Role of N-Acetylcysteine as Adjuvant Therapy on TGF-β and II-6-Mediated Immune Response and Subsequent Fibrosis in Covid-19 Patients Predicted by Crp and D-Dimer Levels
Main Article Content
Abstract
Background: Despite vast amount of completed and ongoing researches, the role of immune system in COVID-19 remains unclear. Widespread lung damage as the result of the disease also often causes pulmonary fibrosis as a sequela. Antioxidant property of N-Acetylcysteine (NAC) has prompted its use as adjuvant therapy in COVID-19, both in immune system regulation and prevention of pulmonary fibrosis. We analyze the role of high dose NAC (>1200 mg/day) in COVID-19 immune response, mediated by major pro-inflammatory COVID-19 cytokines IL-6 and TGF-β, and in preventing subsequent pulmonary fibrosis, predicted by CRP and D-dimer, known parameters of lung damage in COVID-19. Premature increase of TGF-β may play a major role in immune system dysregulation in COVID-19.
Method This is a non-equivalent experimental study in confirmed COVID patients admitted in our hospital between June 2020 to July 2021. Patients were randomly divided unto NAC and control group, and IL-6, TGF-β, CRP and D-dimer levels were measured at admission and after 7 days of administration of NAC.
Result Compared to control group, there are significant decreases of IL-6, CRP, and D-dimer levels (p=.001, .000, and 0.001, respectively) after NAC administration. TGF-β level increases in both control and NAC group, although not significantly.
Conclusion NAC is a beneficial adjunctive therapy in alleviating immune response in COVID-19 as it lowers IL-6 level. NAC also lowers both CRP and D-dimer levels, which suggests that NAC may prevent post COVID-19 pulmonary fibrosis by mitigating lung damage caused by the disease.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Yang CL, Qiu X, Zeng YK, Jiang M, Fan HR, Zhang ZM. Coronavirus disease 2019: A clinical review. Eur Rev Med Pharmacol Sci. 2020;24(8):4585–96.
II. Kunutsor SK, Laukkanen JA. Cardiovascular Complications in COVID-19: A Systematic Review and Meta-analysis. J Infect. 2020;81:139–41.
III. Azer SA. COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect [Internet]. 2020;37(M):100738. Available from: https://doi.org/10.1016/j.nmni.2020.100738
IV. Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after covid-19: Treatment prospects. Pharmaceuticals. 2021;14(8):1–15.
V. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020;34(10):13185–93.
VI. Karkhanei B, Talebi Ghane E, Mehri F. Evaluation of oxidative stress level: total antioxidant capacity, total oxidant status and glutathione activity in patients with COVID-19. New Microbes New Infect [Internet]. 2021;42:100897. Available from: https://doi.org/10.1016/j.nmni.2021.100897
VII. Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N, et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein J [Internet]. 2020;39(6):644–56. Available from: https://doi.org/10.1007/s10930-020-09935-8
VIII. Wong KK, Lee SWH, Kua KP. N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence. J Inflamm Res. 2021;14:2993–3013.
IX. Demot B, Hizon KIM. The Role of N-acetylcysteine on Post Covid-19 Pulmonary Fibrosis. Open Forum Infect Dis. 2021;8:370–1.
X. Alencar JCG de, Moreira C de L, Müller AD, Chaves CE, Fukuhara MA, Silva EA da, et al. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19. Clin Infect Dis. 2020;2:1–35.
XI. Hidayati D. Profil Penduduk Terkonfirmasi Positif Covid-19 Dan Meninggal: Kasus Indonesia Dan Dki Jakarta. J Kependud Indones. 2020;2902:93.
XII. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843–51.
XIII. Faverio P, Rebora P, Rossi E, Del Giudice S, Montanelli F, Garzillo L, et al. Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study. ERJ Open Res. 2022;8(1):8–11.
XIV. Hanum PS, Hanifa Q. The Effectiveness of High-dose N-acetylcysteine in Severe COVID-19 Patients. KELUWIH J Kesehat dan Kedokt. 2021;3(1):22–34.
XV. Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup. N Engl J Med. 2021;384(16):1564–5.
XVI. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol [Internet]. 2018;18(12):773–89. Available from: http://dx.doi.org/10.1038/s41577-018-0066-7
XVII. Hasan J. N-acetylcysteine in Severe COVID-19 : The Possible Mechanism Dear Editor ,. 2020;7(4):7–9.
XVIII. Suresh V, Behera P, Parida D. Therapeutic role of N-acetyl cysteine ( NAC ) for the treatment and / or management of SARS-CoV-2-induced lung damage in hamster model. Eur J Pharmacol. 2023;938.
XIX. Forel J, Guervilly C, Farnarier C, Donati Y, Hraiech S, Persico N, et al. Transforming Growth Factor- β 1 in predicting early lung fibroproliferation in patients with acute respiratory distress syndrome. 2018;3:1–12.
XX. Saito A, Horie M, Nagase T. TGF- β Signaling in Lung Health and Disease. 2018;1–18.
XXI. Hajhossein A, Hossein T, Yaser K. N -Acetylcysteine Effects on Transforming Growth Factor- b and Tumor Necrosis Factor- a Serum Levels as Pro-Fibrotic and Inflammatory Biomarkers in Patients Following ST-Segment Elevation Myocardial Infarction. Drugs Res Dev. 2013;13(3):199–205.
XXII. Sugiura H, Ichikawa T, Liu X, Kobayashi T, Qi X, Kawasaki S, et al. Pulmonary Pharmacology & Therapeutics N-acetyl- L -cysteine inhibits TGF- b 1 -induced profibrotic responses in fibroblasts. Pulm Pharmacol Ther. 2009;22(6):487–91.
XXIII. Ferreira-Gomes M, Kruglov A, Durek P, Heinrich F, Tizian C, Heinz GA, et al. SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat Commun [Internet]. 2021;12(1). Available from: http://dx.doi.org/10.1038/s41467-021-22210-3
XXIV. Karadeniz H, Avano A, Özger HS, Yıldız PA, Erba G, Bozdayı G, et al. The Prognostic Value of Lung Injury and Fibrosis. Biomark Insights. 2022;17:1–7.
XXV. Sheriff A, Kayser S, Brunner P, Vogt B. C-Reactive Protein Triggers Cell Death in Ischemic Cells. Front Immunol. 2021;12(February):1–8.
XXVI. Luan Y, Yin C, Yao Y. Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections. 2021;12(August):1–10.
XXVII. Gaynitdinova V V., Avdeev SN, Merzhoeva ZM, Berikkhanov ZGM, Medvedeva I V., Gorbacheva TL. N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia. Pulmonologiya. 2021;31(1):21–9.
XXVIII. Assimakopoulos SF, Aretha D, Komninos D, Lagadinou M, Leonidou L, Oikonomou I, et al. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia : a two-center retrospective cohort study. Infect Dis (Auckl). 2021;0(0):1–8.
XXIX. Mubarak AR, Esa T, WIdaningsih Y, Bahrun U. D-Dimer Analysis in COVID-19 Patients. 2021.
XXX. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care. 2020;8(1):1–11.
XXXI. Nat JJ, Prod P, Press I, Press I, Rahimi A, Samimagham H, et al. Efficacy of N-acetyl Cysteine in Severe COVID-19 Patients : A Randomized Controlled Phase III Clinical Trial. 2023;(5):1–9.
XXXII. O’Reilly S, Ciechomska M, Cant R, Van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via gremlin protein. J Biol Chem [Internet]. 2014;289(14):9952–60. Available from: http://dx.doi.org/10.1074/jbc.M113.545822
XXXIII. Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: Biology and genetics. Nat Rev Rheumatol [Internet]. 2011;7(5):282–9. Available from: http://dx.doi.org/10.1038/nrrheum.2011.37
XXXIV. Vishnupriya M, Naveenkumar M, Manjima K, Sooryasree N V., Saranya T, Ramya S, et al. Post-COVID pulmonary fibrosis: Therapeutic efficacy using with mesenchymal stem cells – How the lung heals. Eur Rev Med Pharmacol Sci. 2021;25(6):2748–51.
XXXV. Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol [Internet]. 2021; Available from: http://dx.doi.org/10.1038/s41577-021-00536-9